<DOC>
	<DOCNO>NCT01511237</DOCNO>
	<brief_summary>The purpose evaluate efficacy maternal infant perinatal antiretroviral prophylaxis intensification prevention mother-to-child intrapartum transmission HIV-1 woman receive less 8 week antiretroviral prophylaxis pregnancy .</brief_summary>
	<brief_title>Perinatal Antiretroviral Intensification PMTCT HIV Late Comers</brief_title>
	<detailed_description>Design : multicenter , phase III , single-arm trial . Perinatal antiretroviral intensification ( study treatment ) define addition standard care* mother infant : - Mothers : One NVP 200 mg tablet onset labor continuation HAART four week postpartum - Newborn : AZT+3TC+ NVP 2 week , follow AZT+3TC 2 week : - NVP syrup 2 mg/kg every 24 hour seven day , follow NVP syrup 4 mg/kg every 24 hour seven day . Newborns less 2500 g administer 2mg/kg NVP syrup intake - AZT syrup 4 mg/ kg give every 12 hour four week ( preterm infant le 30 week administer 2 mg/kg every 12 hour ; preterm 30-35 week receive 2 mg/kg every 12 hour first 2 week , increase 3 mg/kg next 2 week ) . - 3TC syrup 2 mg/kg every 12 hour four week . - The standard care Thailand define : - Maternal antiretroviral treatment : ZDV 300 mg , 3TC 150mg LPV/r 400/100 twice day start soon possible 14 week pregnancy + ZDV 300 mg every 3 hour labor ; treatment may continue , stop modify delivery upon recommendation internist . - Newborn : ZDV 4 mg/kg every 12 hour 4 week ( ZDV dose adjusted premature infant ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Eligibility . Pregnant woman present prenatal clinic eligible confirm HIVinfected , intend deliver bring infant study site postnatal care least 6 month ; least 18 year old ; give write informed consent participate study , regardless CD4 cell count . Maternal inclusion criterion : Evidence HIV infection , document two serology test obtain two different date ; All HIV infect pregnant woman enrol , either intervention arm observational study group . Women 30 week gestational age start antiretroviral treatment eligible intervention . They actually receive study intervention present labor le 8 week treatment duration ; Women ANC receive standard care enrol observational study group ( infant receive standard care perinatal antiretroviral intensification ) Women le 30 week gestational age start treatment receive standard care also enrol Observational Reference group ; Agreement breastfeed ; Consent participate follow duration study Evidence preexist fetal anomaly incompatible life ; Concurrent participation clinical trial without prior agreement two study team</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HIV-1 infection</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Mother-to-child transmission HIV-1</keyword>
	<keyword>Thailand</keyword>
	<keyword>Developing Countries</keyword>
</DOC>